Hochstrasser K, Niebel J, Lempart K
Klin Wochenschr. 1977 Apr 1;55(7):343-5. doi: 10.1007/BF01488113.
Simultaneous to the liberation of the acid stable trypsin-plasmin-inhibitor from the inter-alpha-trypsininhibitor in vivo, acid labile degradation products are set free. The main product can be estimated by immunological methods. This product is not excreted by the kidney in contrast to the acid stable inhibitor. The product accumulates in serum in different diseases. An increased concentration of this product indicates also an increased turn-over of the inter-alpha-trypsin inhibitor in the case when the concentraton of the intact inter-alpha-trypsin inhibitor or of the filtrable derivative are within normal range.
在体内,与从α-胰蛋白酶抑制剂中释放出酸稳定的胰蛋白酶-纤溶酶抑制剂同时,酸不稳定的降解产物也被释放出来。主要产物可用免疫学方法进行评估。与酸稳定抑制剂不同,该产物不会经肾脏排泄。该产物在不同疾病的血清中会蓄积。当完整的α-胰蛋白酶抑制剂或可滤过衍生物的浓度在正常范围内时,该产物浓度的升高也表明α-胰蛋白酶抑制剂的周转率增加。